Safety perspectives on presently considered drugs for the treatment of COVID-19. (2020)
Attributed to:
Centre for Drug Safety Science (CDSS)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bph.15204
PubMed Identifier: 32681537
Publication URI: http://europepmc.org/abstract/MED/32681537
Type: Journal Article/Review
Volume: 177
Parent Publication: British journal of pharmacology
Issue: 19
ISSN: 0007-1188